title: Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.
abstract: The theme of this review is to summarize the evolving processes in cardiovascular drug discovery and development within a large pharmaceutical company. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the effectiveness of research collaboration between the two constituencies, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized. The need for improved therapy in many cardiovascular indications remains high, but the feasibility in making progress, despite the advances in molecular biology and genomics, is also assessed.
authors.affiliation: F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Gromo
authors.affiliation: Translational Medicine, Cardiovascular and Metabolism, F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Mann
authors.affiliation: Materiamedica, Knutsford WA16 6JR, United Kingdom.
authors.forename: J D
authors.initials: JD
authors.lastname: Fitzgerald
mesh_terms: D002317:Cardiovascular Agents; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods* / Q000458:organization & administration; D004345:Drug Industry / Q000379:methods* / Q000458:organization & administration; D006801:Humans
chemical_list: D002317:Cardiovascular Agents